Why Early, Large-scale Weight Loss Is the Future of Type 2 Diabetes Care
Year: 2025
Type: article
Abstract: Type 2 diabetes has traditionally been viewed as a chronic, progressive condition. However, recent innovations, such as accessible low-calorie diets and newer weight loss medications, are challenging this paradigm. Evidence from clinical trials and mechanistic studies indicates that intentional weight loss, especially early in the disease course, can meaningfully alter its trajectory through reducing ectopic fat and glycemic levels. New medications that reduce "food noise" are particularly valuable in today's obesogenic environments, helping patients regain some control over calorie intake and supporting sustainable lifestyle changes. These therapies can lead to weight loss of ≥10% in type 2 diabetes and may enable newly diagnosed individuals to achieve and maintain normoglycemia for many years. Early, substantial weight loss combined with glycemic normalization has the potential to extend life expectancy, reduce or delay complications associated with obesity and hyperglycemia, improve quality of life, and lower long-term care needs. Beyond weight reduction, additional health benefits are offered by these medications, as they also slow atherosclerosis and preserve kidney function. Building on recent American Diabetes Association-European Association for the Study of Diabetes guideline recommendations, we propose that intentional weight loss at or near the time of diagnosis be considered a central strategy in type 2 diabetes management. To support this shift, proof-of-concept trials should be conducted for assessment of the long-term efficacy and durability of this approach. With success, increased competition and broader access to weight loss medications could lower costs and expand availability-even in low- and middle-income countries, where diabetes rates are rising rapidly-supporting a transformative change in the global standard of care.
Source: Diabetes Care
DOI: 10.2337/dci25-0069
Authors: Naveed Sattar, John B. Buse
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4416216544